Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity

Article metrics


Recent studies of human immunodeficiency virus type 1 (HIV-1) infection in humans and of simian immunodeficiency virus (SIV) in rhesus monkeys have shown that resolution of the acute viral infection and control of the subsequent persistent infection are mediated by the antiviral cellular immune response1,2,3,4,5,6,7,8,9,10,11. We comparatively assessed several vaccine vector delivery systems—three formulations of a plasmid DNA vector, the modified vaccinia Ankara (MVA) virus, and a replication incompetent adenovirus type 5 (Ad5) vector—expressing the SIV gag protein for their ability to elicit such immune responses in monkeys. The vaccines were tested either as a single modality or in combined modality regimens. Here we show that the most effective responses were elicited by a replication-incompetent Ad5 vector, used either alone or as a booster inoculation after priming with a DNA vector. After challenge with a pathogenic HIV–SIV hybrid virus (SHIV), the animals immunized with Ad5 vector exhibited the most pronounced attenuation of the virus infection. The replication-defective adenovirus is a promising vaccine vector for development of an HIV-1 vaccine.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1: Quantification of CD8+ T-cell responses by tetramer analysis during immunization.
Figure 2: Post-challenge viraemia and CD4+ T-cell counts.


  1. 1

    Koup, R. A. et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68, 4650–4655 (1994).

  2. 2

    Borrow, P., Lewicki, H., Hahn, B. H., Shaw, G. M. & Oldstone, M. B. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J. Virol. 68, 6103–6110 (1994).

  3. 3

    Kuroda, M. J. et al. Emergence of CTL coincides with clearance of virus during primary simian immunodeficiency virus infection in rhesus monkeys. J. Immunol. 162, 5127–5133 (1999).

  4. 4

    Klein, M. R. et al. Associations between HLA frequencies and pathogenic features of human immunodeficiency virus type 1 infection in seroconverters from the Amsterdam cohort of homosexual men. J. Infect. Dis. 169, 1244–1249 (1994).

  5. 5

    Musey, L. et al. Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. N. Engl. J. Med. 337, 1267–1274 (1997).

  6. 6

    Pontesilli, O. et al. Longitudinal analysis of human immunodeficiency virus type 1-specific cytotoxic T lymphocyte responses: a predominant gag-specific response is associated with nonprogressive infection. J. Infect. Dis. 178, 1008–1018 (1998).

  7. 7

    Ogg, G. S. et al. Longitudinal phenotypic analysis of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes: correlation with disease progression. J. Virol. 73, 9153–9160 (1999).

  8. 8

    Gallimore, A. et al. Early suppression of SIV replication by CD8+ nef-specific cytotoxic T cells in vaccinated macaques. Nature Med. 1, 1167–1173 (1995).

  9. 9

    Barouch, D. H. et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 290, 486–492 (2000).

  10. 10

    Amara, R. R. et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292, 69–74 (2001).

  11. 11

    Schmitz, J. E. et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 283, 857–860 (1999).

  12. 12

    Newman, M. J., Actor, J. K., Balusubramanian, M. & Jagannath, C. Use of nonionic block copolymers in vaccines and therapeutics. Crit. Rev. Ther. Drug Carrier Syst. 15, 89–142 (1998).

  13. 13

    Miller, M. D., Yamamoto, H., Hughes, A. L., Watkins, D. I. & Letvin, N. L. Definition of an epitope and MHC class I molecule recognized by gag-specific cytotoxic T lymphocytes in SIVmac-infected rhesus monkeys. J. Immunol. 147, 320–329 (1991).

  14. 14

    Allen, T. M. et al. Characterization of the peptide binding motif of a rhesus MHC class I molecule (Mamu-A*01) that binds an immunodominant CTL epitope from simian immunodeficiency virus. J. Immunol. 160, 6062–6071 (1998).

  15. 15

    Egan, M. A. et al. Use of major histocompatibility complex class I/peptide/β2 M tetramers to quantitate CD8(+) cytotoxic T lymphocytes specific for dominant and nondominant viral epitopes in simian-human immunodeficiency virus-infected rhesus monkeys. J. Virol. 73, 5466–5472 (1999).

  16. 16

    Reimann, K. A. et al. An env gene derived from a primary human immunodeficiency virus type 1 isolate confers high in vivo replicative capacity to a chimeric simian/human immunodeficiency virus in rhesus monkeys. J. Virol. 70, 3198–3206 (1996).

  17. 17

    Knapp, L. A., Lehmann, E., Piekarczyk, M. S., Urvater, J. A. & Watkins, D. I. A high frequency of Mamu-A*01 in the rhesus macaque detected by polymerase chain reaction with sequence specific primers and direct sequencing. Tissue Antigens 50, 657–661 (1997).

  18. 18

    Montgomery, D. L. et al. Heterologous and homologous protection against influenza A by DNA vaccination: optimization of DNA vectors. DNA Cell Biol. 12, 777–783 (1993).

  19. 19

    Fu, T. M., Friedman, A., Ulmer, J. B., Liu, M. A. & Donnelly, J. J. Protective cellular immunity: cytotoxic T-lymphocyte responses against dominant and recessive epitopes of influenza virus nucleoprotein induced by DNA immunization. J. Virol. 71, 2715–2721 (1997).

  20. 20

    Wyatt, L. S., Shors, S. T., Murphy, B. R. & Moss, B. Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model. Vaccine 14, 1451–1458 (1996).

Download references


We gratefully acknowledge K. Wright of Laboratory Animal Resources, Merck Research Laboratories, R. Druilhet and R. Colligan of New Iberia Research Center, and M. Hevy and K. Manson of Primedica for their contributions to this research. We are also thankful for assistance from B. Moss and V. Hirsch of the NIH in constructing the recombinant MVA virus.

Author information

Correspondence to Emilio A. Emini.

Supplementary information

Table 1, methods and figure legend (DOC 38 kb)

Figure 1 (GIF 28 kb)

Rights and permissions

Reprints and Permissions

About this article

Further reading


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.